These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 39117725)

  • 41. Construction of Hierarchically Biomimetic Iron Oxide Nanosystems for Macrophage Repolarization-Promoted Immune Checkpoint Blockade of Cancer Immunotherapy.
    Kang Y; Yan J; Han X; Wang X; Wang Y; Song P; Su X; Rauf A; Jin X; Pu F; Zhang H
    ACS Appl Mater Interfaces; 2024 Jul; 16(28):36131-36141. PubMed ID: 38979627
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth.
    Lee J; Shin YJ; Lee K; Cho HJ; Sa JK; Lee SY; Kim SH; Lee J; Yoon Y; Nam DH
    Cancer Res Treat; 2018 Jul; 50(3):1009-1022. PubMed ID: 29129044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti-PD-1/PD-L1 cancer immunotherapy.
    Yu L; Huang K; Liao Y; Wang L; Sethi G; Ma Z
    Cell Prolif; 2024 Aug; 57(8):e13644. PubMed ID: 38594879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells.
    Huang BY; Zhan YP; Zong WJ; Yu CJ; Li JF; Qu YM; Han S
    PLoS One; 2015; 10(8):e0134715. PubMed ID: 26266810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity.
    Doan P; Nguyen P; Murugesan A; Candeias NR; Yli-Harja O; Kandhavelu M
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune Checkpoint-Blocking Nanocages Cross the Blood-Brain Barrier and Impede Brain Tumor Growth.
    Kim M; Yoon HJ; Lee C; Lee M; Park RW; Lee B; Park EJ; Kim S
    ACS Biomater Sci Eng; 2024 Jan; 10(1):575-587. PubMed ID: 38150627
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
    Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
    Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics.
    Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R
    Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.
    Wang X; Guo G; Guan H; Yu Y; Lu J; Yu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):87. PubMed ID: 30777100
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
    Puigdelloses M; Garcia-Moure M; Labiano S; Laspidea V; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; De la Nava D; Ausejo I; Hervás-Stubbs S; Herrador G; Chen Z; Hambardzumyan D; Patino Garcia A; Jiang H; Gomez-Manzano C; Fueyo J; Gállego Pérez-Larraya J; Alonso M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy.
    Xiong W; Qi L; Jiang N; Zhao Q; Chen L; Jiang X; Li Y; Zhou Z; Shen J
    ACS Appl Mater Interfaces; 2021 Feb; 13(7):8026-8041. PubMed ID: 33577301
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.
    Fumarola C; La Monica S; Bonelli M; Zoppi S; Alfieri R; Galetti M; Gnetti L; Campanini N; Pozzi G; Cavazzoni A; Mazzaschi G; Silini EM; Buti S; Petronini PG
    Biochem Pharmacol; 2024 Aug; 226():116397. PubMed ID: 38944394
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design, Synthesis, and Evaluation of
    OuYang Y; Gao J; Zhao L; Lu J; Zhong H; Tang H; Jin S; Yue L; Li Y; Guo W; Xu Q; Lai Y
    J Med Chem; 2021 Jun; 64(11):7646-7666. PubMed ID: 34037385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergy between glutamate modulation and anti-programmed cell death protein 1 immunotherapy for glioblastoma.
    Medikonda R; Choi J; Pant A; Saleh L; Routkevitch D; Tong L; Belcaid Z; Kim YH; Jackson CM; Jackson C; Mathios D; Xia Y; Shah PP; Patel K; Kim T; Srivastava S; Huq S; Ehresman J; Pennington Z; Tyler B; Brem H; Lim M
    J Neurosurg; 2022 Feb; 136(2):379-388. PubMed ID: 34388730
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells.
    Cheng YC; Tsai WC; Sung YC; Chang HH; Chen Y
    Cell Physiol Biochem; 2018; 45(2):819-831. PubMed ID: 29414809
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
    Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
    Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.